Key Highlights

  • Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) fell 8.81% to USD 0.2610 in pre-market trading on Wednesday, October 28, 2026, its second straight pre-market loss, with nothing company-specific announced on or just before that date.
  • The quarter ended June 30, 2026 produced no revenue, a net loss of about USD 3.8 million and cash of about USD 4.6 million, as reported in the quarterly filing of Friday, August 14, 2026.
  • Lead candidate Nu-3, a topical gel for infected diabetic foot ulcers, is being readied for a Phase 2a study. The release of Thursday, October 1, 2026 listed an investor conference and a poster of preclinical data on Thursday, October 22, 2026.
  • A research note of Wednesday, August 26, 2026 projected that cash will last through the end of 2026. Thin pre-market quotes can change before the open.

The Session in Context

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is a clinical-stage developer of antimicrobial drugs built on its Bisphosphocin platform. Its pre-market price of USD 0.2610 on Wednesday, October 28, 2026 sits 8.81% below the prior close, which simple arithmetic places at about USD 0.286. The stock printed USD 0.2632 pre-market on Tuesday, October 27, 2026, so it has been hovering in a narrow band. No company announcement dated on or just before October 28 accompanied the move.

What the Quarterly Report Shows

Quarterly filings for the three months to June 30, 2026 show no revenue. Research and development spending rose to USD 503,000 from USD 147,000, while general and administrative costs jumped to about USD 3.3 million from USD 489,000, leaving a net loss near USD 3.8 million. An April 2026 Series C convertible preferred placement brought in roughly USD 6.8 million net. The Phase 2a Nu-3 study, registered as NCT07565506, will compare 2%, 5% and 10% gel strengths applied daily for 14 days, and no start date has been given. The October 1 release also flagged the ThinkEquity conference on Thursday, October 15, 2026 and IDWeek from Wednesday, October 21, 2026.

Upside and Downside Scenarios

Bulls point to preclinical findings presented at IDWeek and to the Phase 2a design, where a clear antimicrobial effect at Day 7 and Day 14 could justify a Phase 2b study. Bears see cash of about USD 4.6 million set against a quarterly loss of about USD 3.8 million, which signals a near-term need for money. The named risks are dilution from new shares or conversion of the Series C preferred, Nasdaq minimum bid compliance with the stock below USD 1.00, and clinical risk, since preclinical findings may not carry over to patients. Watch the trial start date, any financing, the next quarterly report and the Federal Reserve decision scheduled for later on Wednesday, October 28, 2026.

Where Things Stand

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is holding close to the prior session's lows, and the further 8.81% pre-market drop looks consistent with thin liquidity and a funding need ahead of the trial. The key figure is about USD 4.6 million of cash at June 30, 2026, against a quarterly net loss of about USD 3.8 million. Catalysts to come are the Phase 2a start, any financing and the Federal Reserve decision on Wednesday, October 28, 2026. Pre-market prices are snapshots that can change, and this is not investment advice.